Phase II Clinical Study Results of UBT251 Injection Presented at 2026 American Diabetes Association (ADA) Scientific Sessions

Guangdong, China, June 8 2026 - The United Laboratories International Holdings Limited ("TUL", the "Company", or the "Group"; Stock Code: 3933) showcased its self-developed Class 1 innovative drug, UBT251 Injection, a triple agonist of GLP-1R/GIPR/GCGR, at the 86th American Diabetes Association ("ADA") Scientific Sessions.

UBT251 was selected for a Late-Breaking Abstracts ("LBA") program at the 86th ADA Scientific Sessions based on its outstanding clinical data and was further officially chosen by the ADA for presentation of both the Press Briefing and Poster sessions. On June 6, Central Time, Professor Zhiguang Zhou from The Second Xiangya Hospital of Central South University, the lead investigator of the study, formally presented the primary results of the Phase II clinical study of UBT251 in Chinese participants with overweight or obesity.

Study Design

This randomized, double-blind, placebo-controlled trial enrolled a total of 205 Chinese participants with obesity (BMI ≥ 28.0 kg/m²) or overweight (24.0 kg/m² ≤ BMI < 28.0 kg/m²) with at least one weight-related comorbidity. The baseline mean body weight of the participants was 92.2 kg, with a baseline mean BMI of 33.1 kg/m².

Participants were randomized in a 2:1:1:2:2 ratio to receive once-weekly subcutaneous injections of UBT251 at doses of 2.0 mg, 4.0 mg (initial dose: 0.5 mg), 4.0 mg (initial dose: 1.0 mg) and 6.0 mg, or placebo, for a treatment duration of 24 weeks.

The primary endpoint of the study was the percentage change in body weight from baseline after 24 weeks of treatment.

Primary Study Results

- After 24 weeks of treatment, the least-squares mean percentage change in body weight from baseline ranged from -13.6% to -19.7% in the UBT251 groups, significantly outperforming the placebo group (-2.0%). Participants had not yet reached a body weight plateau by the end of the treatment period.
- Secondary efficacy endpoints showed that up to 98.1% of participants in the UBT251 groups achieved ≥5% weight loss from baseline; up to 89.8% achieved ≥10% weight loss; and up to 48.4% achieved ≥20% weight loss from baseline.
- The safety and tolerability profile of UBT251 was generally consistent with that of other GLP-1 receptor agonists. No apparent dose-dependent trend was observed in the incidence of treatment-emergent adverse events ("TEAE") during the treatment period.

Conclusion

The Phase II clinical study of UBT251 in Chinese participants with overweight or obesity demonstrated clinically meaningful weight loss and a favourable safety profile. Based on the data generated to date, TUL is actively advancing subsequent Phase III pivotal clinical study to further evaluate the clinical value of UBT251 in the treatment of metabolic diseases.

About UBT251

UBT251 is a long-acting triple receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and GCG (glucagon), independently developed by The United Bio-Technology (Hengqing) Co., Ltd. ("United Biotechnology"), a wholly owned subsidiary of the Company. To date, UBT251 has been approved to conduct clinical trials in China and/or the United States for multiple indications, including adult type 2 diabetes, overweight or obesity, chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH). In March 2025, United Biotechnology and the Company entered into an exclusive licensing agreement with Novo Nordisk A/S for UBT251.

About TUL

Founded in 1990, TUL (HKEX: 3933) focuses on the R&D, production and sales of pharmaceuticals, and is one of the leading comprehensive pharmaceutical companies in China. Upholding its corporate tenet of "Making Life More Valuable", the Group has established a diversified industrial structure covering finished products, bulk medicine, biopharmaceuticals and animal healthcare, and continues to optimize its vertically integrated business model. TUL currently boasts eleven production bases, covering intermediate products, bulk medicine, finished products, health & wellness products, animal healthcare products, empty capsule casings and medical devices, with a global sales networks. TUL is presently a constituent of the Hang Seng Composite Index Series, and maintains MSCI ESG rating at AA, which is an industry leading rating. For more information, please visit www.tul.com.cn.

For further enquiries, please contact:

TUL Media:
iPR Limited
Tina Law / Joann Fang
+852 2136 6185
tul@ipr.com.hk

TUL Investor Relations:
Karen Yang / Sandy He / Mercy Mo
+86 760 8713 3970/ 8713 3742/ 8713 3724
tulir@tul.com.hk